Business Context and Reporting Period
This Form 8-K is a current report filed by Bristol-Myers Squibb Company on January 8, 2024. The filing serves primarily to disclose a Regulation FD (Fair Disclosure) event where the Company posted an investor presentation to its website.
Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document references an attached investor presentation (Exhibit 99.1) which likely contains these figures, but the text of the 8-K itself does not list them.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The report focuses solely on the dissemination of the investor presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company disclosed the availability of an investor presentation dated January 8, 2024, on its investor relations website.
Legal Disclaimer: The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings. The furnishing of this information is not an admission as to the materiality of the information contained therein.
Key Facts for Investor Verification
- Verify the contents of the Investor Presentation (Exhibit 99.1) attached to this filing for actual financial data, guidance, and strategic outlook.
- Note that the presentation is not legally "filed" with the SEC and carries specific liability limitations under the Exchange Act.
- Confirm the trading symbols for the Company's registered securities: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).